MARKET

TNGX

TNGX

Tango Therapeutics Inc
NASDAQ
27.31
+0.68
+2.53%
Opening 15:22 07/27 EDT
OPEN
26.78
PREV CLOSE
26.63
HIGH
28.09
LOW
26.52
VOLUME
1.40M
TURNOVER
--
52 WEEK HIGH
34.39
52 WEEK LOW
5.77
MARKET CAP
4.45B
P/E (TTM)
-33.0449
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TNGX last week (0720-0724)?
Weekly Report · 9h ago
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Ascendis Pharma (ASND) and Monopar Therapeutics Inc (MNPR)
TipRanks · 4d ago
Weekly Report: what happened at TNGX last week (0713-0717)?
Weekly Report · 07/20 09:29
Mizuho Securities Reaffirms Their Buy Rating on Tango Therapeutics (TNGX)
TipRanks · 07/19 12:15
Tango Therapeutics Is Maintained at Outperform by Mizuho
Dow Jones · 07/17 19:10
Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40
Benzinga · 07/17 18:59
Midday Fly By: Netflix forecast fuels fears, SpaceX tumbles after scrubbing test
TipRanks · 07/17 16:06
More
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The Company is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

Webull offers Tango Therapeutics Inc stock information, including NASDAQ: TNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNGX stock methods without spending real money on the virtual paper trading platform.